For people suffering from treatment-resistant depression, ketamine known in the drug world at “Special K” can provide immediate relief for their symptoms. The discovery of its anti-depressant properties has been called “arguably the most important discovery in half a century” of depressive research. The drug “rapidly spurs the growth of new synapses, the connections between brain cells, and is associated with reversal of the atrophy caused by chronic stress.”
Now in the largest controlled study of ketamine to date, Dr. John Crystal professor of psychiatry at Yale has confirmed those assumptions. The study administered a single small intravenous (IV) dose of Ketamine to patients with severe depression. Within one day 64% of patients reported fewer symptoms and the results outweighed those given midazolam, an asethic drug used as the control. Only 28% of patients using midazolam reported any sort of improvement.
Read the full article at WRR